{"id":"https://openalex.org/W1982959429","doi":"https://doi.org/10.1158/1078-0432.ccr-12-0589","title":"Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations","display_name":"Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations","publication_year":2012,"publication_date":"2012-07-06","ids":{"openalex":"https://openalex.org/W1982959429","doi":"https://doi.org/10.1158/1078-0432.ccr-12-0589","mag":"1982959429","pmid":"https://pubmed.ncbi.nlm.nih.gov/22767670"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.ccr-12-0589","doi":"https://doi.org/10.1158/1078-0432.ccr-12-0589","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-12-0589","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016973435","display_name":"Elizabeth Claire Dees","orcid":"https://orcid.org/0000-0003-4004-7316","observed_orcids":["https://orcid.org/0000-0003-4004-7316"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]},{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"E. Claire Dees","raw_affiliation_strings":["Authors' Affiliations:\u20081UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina; 2University of Pennsylvania; 3Fox Chase Cancer Center, Philadelphia, Pennsylvania; 4Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; and 5Sarah Cannon Research Institute, Nashville, Tennessee","Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts","Sarah Cannon Research Institute, Nashville, Tennessee","University of Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina; 2University of Pennsylvania; 3Fox Chase Cancer Center, Philadelphia, Pennsylvania; 4Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; and 5Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I1289437631","https://openalex.org/I4390039329","https://openalex.org/I79576946"]},{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4405270001"]},{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":[]},{"raw_affiliation_string":"University of Pennsylvania","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110382646","display_name":"Roger B. Cohen","orcid":"https://orcid.org/0009-0004-7423-2653","observed_orcids":["https://orcid.org/0009-0004-7423-2653"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]},{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Roger B. Cohen","raw_affiliation_strings":["Authors' Affiliations:\u20081UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina; 2University of Pennsylvania; 3Fox Chase Cancer Center, Philadelphia, Pennsylvania; 4Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; and 5Sarah Cannon Research Institute, Nashville, Tennessee","Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts","Sarah Cannon Research Institute, Nashville, Tennessee","University of Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina; 2University of Pennsylvania; 3Fox Chase Cancer Center, Philadelphia, Pennsylvania; 4Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; and 5Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I1289437631","https://openalex.org/I4390039329","https://openalex.org/I79576946"]},{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4405270001"]},{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":[]},{"raw_affiliation_string":"University of Pennsylvania","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085336500","display_name":"Margaret von Mehren","orcid":"https://orcid.org/0000-0001-6158-890X","observed_orcids":["https://orcid.org/0000-0001-6158-890X"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]},{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Margaret von Mehren","raw_affiliation_strings":["Authors' Affiliations:\u20081UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina; 2University of Pennsylvania; 3Fox Chase Cancer Center, Philadelphia, Pennsylvania; 4Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; and 5Sarah Cannon Research Institute, Nashville, Tennessee","Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts","Sarah Cannon Research Institute, Nashville, Tennessee","University of Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina; 2University of Pennsylvania; 3Fox Chase Cancer Center, Philadelphia, Pennsylvania; 4Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; and 5Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I1289437631","https://openalex.org/I4390039329","https://openalex.org/I79576946"]},{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4405270001"]},{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":[]},{"raw_affiliation_string":"University of Pennsylvania","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014554706","display_name":"Thomas E. Stinchcombe","orcid":"https://orcid.org/0000-0002-3595-8011","observed_orcids":["https://orcid.org/0000-0002-3595-8011"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]},{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas E. Stinchcombe","raw_affiliation_strings":["Authors' Affiliations:\u20081UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina; 2University of Pennsylvania; 3Fox Chase Cancer Center, Philadelphia, Pennsylvania; 4Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; and 5Sarah Cannon Research Institute, Nashville, Tennessee","Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts","Sarah Cannon Research Institute, Nashville, Tennessee","University of Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina; 2University of Pennsylvania; 3Fox Chase Cancer Center, Philadelphia, Pennsylvania; 4Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; and 5Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I1289437631","https://openalex.org/I4390039329","https://openalex.org/I79576946"]},{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4405270001"]},{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":[]},{"raw_affiliation_string":"University of Pennsylvania","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100321336","display_name":"Hua Liu","orcid":"https://orcid.org/0000-0003-2798-3337","observed_orcids":["https://orcid.org/0000-0003-2798-3337","https://orcid.org/0009-0007-8715-2988"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]},{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hua Liu","raw_affiliation_strings":["Authors' Affiliations:\u20081UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina; 2University of Pennsylvania; 3Fox Chase Cancer Center, Philadelphia, Pennsylvania; 4Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; and 5Sarah Cannon Research Institute, Nashville, Tennessee","Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts","Sarah Cannon Research Institute, Nashville, Tennessee","University of Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina; 2University of Pennsylvania; 3Fox Chase Cancer Center, Philadelphia, Pennsylvania; 4Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; and 5Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I1289437631","https://openalex.org/I4390039329","https://openalex.org/I79576946"]},{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4405270001"]},{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":[]},{"raw_affiliation_string":"University of Pennsylvania","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044490765","display_name":"Karthik Venkatakrishnan","orcid":"https://orcid.org/0000-0003-4039-9813","observed_orcids":["https://orcid.org/0000-0003-4039-9813"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]},{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karthik Venkatakrishnan","raw_affiliation_strings":["Authors' Affiliations:\u20081UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina; 2University of Pennsylvania; 3Fox Chase Cancer Center, Philadelphia, Pennsylvania; 4Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; and 5Sarah Cannon Research Institute, Nashville, Tennessee","Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts","Sarah Cannon Research Institute, Nashville, Tennessee","University of Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina; 2University of Pennsylvania; 3Fox Chase Cancer Center, Philadelphia, Pennsylvania; 4Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; and 5Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I1289437631","https://openalex.org/I4390039329","https://openalex.org/I79576946"]},{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4405270001"]},{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":[]},{"raw_affiliation_string":"University of Pennsylvania","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009817418","display_name":"Mark G Manfredi","orcid":"https://orcid.org/0000-0002-5920-8784","observed_orcids":["https://orcid.org/0000-0002-5920-8784"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]},{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark Manfredi","raw_affiliation_strings":["Authors' Affiliations:\u20081UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina; 2University of Pennsylvania; 3Fox Chase Cancer Center, Philadelphia, Pennsylvania; 4Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; and 5Sarah Cannon Research Institute, Nashville, Tennessee","Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts","Sarah Cannon Research Institute, Nashville, Tennessee","University of Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina; 2University of Pennsylvania; 3Fox Chase Cancer Center, Philadelphia, Pennsylvania; 4Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; and 5Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I1289437631","https://openalex.org/I4390039329","https://openalex.org/I79576946"]},{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4405270001"]},{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":[]},{"raw_affiliation_string":"University of Pennsylvania","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069781389","display_name":"Howard J. Fingert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]},{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Howard Fingert","raw_affiliation_strings":["Authors' Affiliations:\u20081UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina; 2University of Pennsylvania; 3Fox Chase Cancer Center, Philadelphia, Pennsylvania; 4Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; and 5Sarah Cannon Research Institute, Nashville, Tennessee","Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts","Sarah Cannon Research Institute, Nashville, Tennessee","University of Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina; 2University of Pennsylvania; 3Fox Chase Cancer Center, Philadelphia, Pennsylvania; 4Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; and 5Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I1289437631","https://openalex.org/I4390039329","https://openalex.org/I79576946"]},{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4405270001"]},{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":[]},{"raw_affiliation_string":"University of Pennsylvania","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072308451","display_name":"Howard A. Burris","orcid":"https://orcid.org/0000-0002-1501-2931","observed_orcids":["https://orcid.org/0000-0002-1501-2931"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]},{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Howard A. Burris","raw_affiliation_strings":["Authors' Affiliations:\u20081UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina; 2University of Pennsylvania; 3Fox Chase Cancer Center, Philadelphia, Pennsylvania; 4Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; and 5Sarah Cannon Research Institute, Nashville, Tennessee","Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts","Sarah Cannon Research Institute, Nashville, Tennessee","University of Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina; 2University of Pennsylvania; 3Fox Chase Cancer Center, Philadelphia, Pennsylvania; 4Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; and 5Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I1289437631","https://openalex.org/I4390039329","https://openalex.org/I79576946"]},{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4405270001"]},{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":[]},{"raw_affiliation_string":"University of Pennsylvania","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5103514741","display_name":"Jeffrey R. Infante","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]},{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey R. Infante","raw_affiliation_strings":["Authors' Affiliations:\u20081UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina; 2University of Pennsylvania; 3Fox Chase Cancer Center, Philadelphia, Pennsylvania; 4Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; and 5Sarah Cannon Research Institute, Nashville, Tennessee","Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts","Sarah Cannon Research Institute, Nashville, Tennessee","University of Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina; 2University of Pennsylvania; 3Fox Chase Cancer Center, Philadelphia, Pennsylvania; 4Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; and 5Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I1289437631","https://openalex.org/I4390039329","https://openalex.org/I79576946"]},{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I4405270001"]},{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, Tennessee","institution_ids":[]},{"raw_affiliation_string":"University of Pennsylvania","institution_ids":["https://openalex.org/I79576946"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5016973435"],"corresponding_institution_ids":["https://openalex.org/I114027177","https://openalex.org/I1289437631","https://openalex.org/I4390039329","https://openalex.org/I4405270001","https://openalex.org/I79576946"],"apc_list":null,"apc_paid":null,"fwci":8.0496,"has_fulltext":false,"cited_by_count":157,"citation_normalized_percentile":{"value":0.98471383,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":100},"biblio":{"volume":"18","issue":"17","first_page":"4775","last_page":"4784"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10492","display_name":"Microtubule and mitosis dynamics","score":0.9750999808311462,"subfield":{"id":"https://openalex.org/subfields/1307","display_name":"Cell Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10492","display_name":"Microtubule and mitosis dynamics","score":0.9750999808311462,"subfield":{"id":"https://openalex.org/subfields/1307","display_name":"Cell Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.0066999997943639755,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Synthesis and biological activity","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mln8237","display_name":"MLN8237","score":0.9940000176429749},{"id":"https://openalex.org/keywords/alisertib","display_name":"alisertib","score":0.9739999771118164},{"id":"https://openalex.org/keywords/aurora-a-kinase-inhibitor","display_name":"Aurora A kinase inhibitor","score":0.996999979019165},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.9200000166893005},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8659999966621399},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9629999995231628},{"id":"https://openalex.org/keywords/relative-bioavailability","display_name":"relative bioavailability","score":0.9340000152587891},{"id":"https://openalex.org/keywords/enteric-coated-tablets","display_name":"enteric-coated tablets","score":0.8939999938011169},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.7710000276565552},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.703000009059906},{"id":"https://openalex.org/keywords/oral-anticancer-drugs","display_name":"oral anticancer drugs","score":0.48399999737739563}],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8129469752311707},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7941105365753174},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.7032175660133362},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6370929479598999},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.6242384910583496},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5722648501396179},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.5682628154754639},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5074185729026794},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.4367053508758545},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.4132269322872162},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4083147943019867},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.37771931290626526},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3436765968799591},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.22499492764472961},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D001381","descriptor_name":"Azepines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001381","descriptor_name":"Azepines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001381","descriptor_name":"Azepines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001381","descriptor_name":"Azepines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001381","descriptor_name":"Azepines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001381","descriptor_name":"Azepines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001381","descriptor_name":"Azepines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D001381","descriptor_name":"Azepines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D001381","descriptor_name":"Azepines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001706","descriptor_name":"Biopsy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001706","descriptor_name":"Biopsy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001706","descriptor_name":"Biopsy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005221","descriptor_name":"Fatigue","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D005221","descriptor_name":"Fatigue","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D005221","descriptor_name":"Fatigue","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009325","descriptor_name":"Nausea","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D009325","descriptor_name":"Nausea","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D009325","descriptor_name":"Nausea","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D009367","descriptor_name":"Neoplasm Staging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009367","descriptor_name":"Neoplasm Staging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009367","descriptor_name":"Neoplasm Staging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D009503","descriptor_name":"Neutropenia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D009503","descriptor_name":"Neutropenia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D009503","descriptor_name":"Neutropenia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D017346","descriptor_name":"Protein Serine-Threonine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D017346","descriptor_name":"Protein Serine-Threonine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D017346","descriptor_name":"Protein Serine-Threonine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D017346","descriptor_name":"Protein Serine-Threonine Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D017346","descriptor_name":"Protein Serine-Threonine Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D017346","descriptor_name":"Protein Serine-Threonine Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064127","descriptor_name":"Aurora Kinases","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064127","descriptor_name":"Aurora Kinases","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064127","descriptor_name":"Aurora Kinases","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.ccr-12-0589","doi":"https://doi.org/10.1158/1078-0432.ccr-12-0589","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-12-0589","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},{"id":"pmid:22767670","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22767670","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical cancer research : an official journal of the American Association for Cancer Research","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.8399999737739563,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320333265","display_name":"Takeda Oncology","ror":"https://ror.org/05vm7p871"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":37,"referenced_works":["https://openalex.org/W1556655356","https://openalex.org/W1657157395","https://openalex.org/W1979795699","https://openalex.org/W1981073960","https://openalex.org/W1985338536","https://openalex.org/W2006113261","https://openalex.org/W2007608739","https://openalex.org/W2037988871","https://openalex.org/W2048097747","https://openalex.org/W2064261028","https://openalex.org/W2066906356","https://openalex.org/W2069910776","https://openalex.org/W2079788104","https://openalex.org/W2085227881","https://openalex.org/W2095523826","https://openalex.org/W2107019456","https://openalex.org/W2114291028","https://openalex.org/W2116565287","https://openalex.org/W2119974970","https://openalex.org/W2126572395","https://openalex.org/W2126592740","https://openalex.org/W2127621535","https://openalex.org/W2137429755","https://openalex.org/W2138805078","https://openalex.org/W2139248078","https://openalex.org/W2140029079","https://openalex.org/W2144977250","https://openalex.org/W2148375003","https://openalex.org/W2150548655","https://openalex.org/W2150599921","https://openalex.org/W2153081604","https://openalex.org/W2159801780","https://openalex.org/W2168050705","https://openalex.org/W2170710435","https://openalex.org/W2241093797","https://openalex.org/W2249679233","https://openalex.org/W2589373649"],"related_works":["https://openalex.org/W4311628015","https://openalex.org/W3191427281","https://openalex.org/W2087016115","https://openalex.org/W2560259057","https://openalex.org/W2000475715","https://openalex.org/W4312909839","https://openalex.org/W130051642","https://openalex.org/W2589373649","https://openalex.org/W189281016","https://openalex.org/W4381480068"],"abstract_inverted_index":{"PURPOSE:":[0],"This":[1,208],"phase":[2,224],"I":[3],"study":[4],"evaluated":[5,80,99,244],"the":[6,13,70,84,139,149,152,156,247],"safety,":[7],"pharmacokinetics,":[8],"pharmacodynamics,":[9],"and":[10,69,104,116,125,130,171,192,215,253],"efficacy":[11],"of":[12,38,73,91,95,143,155,211,227,249],"investigational":[14],"oral":[15],"drug":[16],"MLN8237":[17,41,65,92,166,194,212,228],"(alisertib),":[18],"a":[19,173,183],"small-molecule":[20],"Aurora":[21],"A":[22],"kinase":[23],"(AAK)":[24],"inhibitor,":[25],"in":[26,81,100,218,238,246],"87":[27],"adult":[28],"patients":[29,39,200],"with":[30,176],"advanced":[31],"solid":[32,251],"tumors.":[33],"EXPERIMENTAL":[34],"DESIGN:":[35],"Sequential":[36],"cohorts":[37],"received":[40,193],"5":[42],"to":[43,83,106],"150":[44],"mg":[45,145,231],"orally":[46,234],"once":[47],"daily":[48,51,147,233],"or":[49,55],"twice":[50,146,232],"for":[52,128,187,195,204,235],"7,":[53,172],"14,":[54],"21":[56],"days,":[57],"followed":[58],"by":[59],"14":[60],"days'":[61],"rest":[62],"per":[63],"cycle.":[64],"pharmacokinetics":[66,217],"was":[67,79,135,160],"characterized,":[68],"relative":[71],"bioavailability":[72],"an":[74],"enteric-coated":[75],"tablet":[76],"(ECT)":[77],"formulation":[78],"reference":[82],"original":[85],"powder-in-capsule":[86],"(PIC)":[87],"formulation.":[88],"Pharmacodynamic":[89],"effects":[90],"on":[93,148,168],"inhibition":[94],"AAK":[96,177],"activity":[97],"were":[98,108,126],"skin":[101,157],"biopsies.":[102],"Tolerability":[103],"response":[105,185],"treatment":[107,248],"assessed.":[109],"RESULTS:":[110],"Common":[111],"toxicities":[112],"included":[113],"fatigue,":[114],"nausea,":[115],"neutropenia.":[117],"Plasma":[118],"exposures":[119],"increased":[120,161],"dose":[121,142,226],"proportionally":[122],"(5-150":[123],"mg/d),":[124],"similar":[127],"PIC":[129],"ECT.":[131],"The":[132,222],"terminal":[133],"half-life":[134],"23":[136],"hours.":[137],"At":[138],"maximum":[140],"tolerated":[141],"50":[144,230],"7-day":[150],"schedule,":[151],"mitotic":[153],"index":[154],"basal":[158],"epithelium":[159],"within":[162],"24":[163],"hours":[164],"after":[165],"administration":[167],"days":[169,237],"1":[170,190],"finding":[174],"consistent":[175],"inhibition.":[178],"One":[179],"(1%)":[180],"patient":[181,220],"achieved":[182,201],"partial":[184],"lasting":[186],"more":[188],"than":[189],"year":[191],"51":[196],"cycles;":[197],"20":[198],"(23%)":[199],"stable":[202],"disease":[203],"\u22653":[205],"months.":[206],"CONCLUSIONS:":[207],"first-in-human":[209],"trial":[210],"showed":[213],"tolerability":[214],"favorable":[216],"this":[219],"population.":[221],"recommended":[223],"II":[225],"is":[229,242],"7":[236],"21-day":[239],"cycles,":[240],"which":[241],"being":[243],"further":[245],"various":[250],"tumors":[252],"hematologic":[254],"malignancies.":[255]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":11},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":15},{"year":2018,"cited_by_count":10},{"year":2017,"cited_by_count":13},{"year":2016,"cited_by_count":16},{"year":2015,"cited_by_count":31},{"year":2014,"cited_by_count":15},{"year":2013,"cited_by_count":13},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2025-10-10T00:00:00"}